248 related articles for article (PubMed ID: 7514153)
1. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line.
Zalcberg JR; Hu XF; Wall DM; Mirski S; Cole S; Nadalin G; De Luise M; Parkin JD; Vrazas V; Campbell L
Int J Cancer; 1994 May; 57(4):522-8. PubMed ID: 7514153
[TBL] [Abstract][Full Text] [Related]
2. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Fisher LM
Br J Cancer; 1993 Mar; 67(3):456-63. PubMed ID: 8382508
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.
Zalcberg JR; Hu XF; Ching M; Wakeling A; Wall DM; Marschner IC; de Luise M
Cancer Chemother Pharmacol; 1993; 33(2):123-9. PubMed ID: 7903222
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.
Kavallaris M; Haber M; Norris MD; Pittman SM; Reed C; Stewart BW
Cancer Lett; 1990 Jun; 51(3):193-201. PubMed ID: 1972035
[TBL] [Abstract][Full Text] [Related]
5. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
6. Nuclear DNA content and chromatin texture in multidrug-resistant human leukemic cell lines.
Dufer J; Millot-Broglio C; Oum'Hamed Z; Liautaud-Roger F; Joly P; Desplaces A; Jardillier JC
Int J Cancer; 1995 Jan; 60(1):108-14. PubMed ID: 7814142
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
8. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
9. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
10. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
11. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
12. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.
Eijdems EW; Borst P; Jongsma AP; de Jong S; de Vries EG; van Groenigen M; Versantvoort CH; Nieuwint AW; Baas F
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3498-502. PubMed ID: 1348862
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
14. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
15. Structure-dependent antitumor activities of novel anthracyclines YM1, YM3, YM4 and YM6: drug transport properties and effects on biomacromolecule synthesis in drug sensitive and resistant leukemia cells.
Jiang XR; Macey MG; Kelsey SM; Collins PW; Gutteridge CN; Miki T; Adachi K; Yamabe S; Newland AC
J Chemother; 1993 Oct; 5(5):334-43. PubMed ID: 7508975
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias.
Gekeler V; Beck J; Noller A; Wilisch A; Frese G; Neumann M; Handgretinger R; Ehninger G; Probst H; Niethammer D
Ann Hematol; 1994; 69 Suppl 1():S19-24. PubMed ID: 7914748
[TBL] [Abstract][Full Text] [Related]
17. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
[TBL] [Abstract][Full Text] [Related]
18. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
[TBL] [Abstract][Full Text] [Related]
19. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
20. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
